101 results
8-K
EX-10.28
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.33
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.23
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.29
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.30
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.6
twt5s7e
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.20
e3ctyao7s9f 124
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.22
ufr4ruz
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.24
xohpb82 2th41ci9fp
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.19
qr6r8a
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.27
yiogpeub69hmec
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.32
yo0nyzwjvgis2 1bg
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.21
hy97gp kgkt01ci
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.26
qnytb4yw22vvvfls
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.31
zh4wjg9tdvl2xwlnliub
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.1
3qm7rfcdys9h
4 Dec 23
Other Events
5:10pm
S-4/A
EX-10.33
6zcofoxjku 3b50
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.34
atxd9yowhxkuzk
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.36
to7oj 2ma6hgsl
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm